TABLE 2.

Eligibility criteria for qualitative research for stage 5 (qualitative lexicon research).

Patients Individuals aged 18–65 years, diagnosed with moderate‐to‐severe a haemophilia A or B. Currently using a factor replacement regimen as primary treatment, on an on‐demand or prophylactic dosing schedule. Representing a population likely to be eligible for future genetic treatment. Must be open to considering gene therapy as a future treatment and have not previously participated in a gene therapy clinical trial.

Caregivers Caregivers (who are primarily family caregivers) to an individual with moderate‐to‐severe a haemophilia A or B who fall under the specifications noted for patient recruitment above. The person they care for has not previously participated in a gene therapy clinical trial.

Haematologists Haematologists are actively b involved in directly treating an adequate proportion c of people with moderate‐to‐severe a haemophilia. Practice across a diverse mix of practice locations. Must be open to considering gene therapy for PWH.

^a Moderate defined as factor levels 1–5%, and severe defined as factor levels < 1%. ¹⁸

^b Defined as treating at least 25% of the total number of patients treated.

^c Defined as compromising at least 50% of their working hours.